雷替曲塞二线治疗晚期结直肠癌的疗效分析

发布时间：2018-05-18 09:52

本文选题：雷替曲塞 + 晚期结直肠癌　；参考：《郑州大学学报(医学版)》2017年03期

【摘要】：目的:观察雷替曲塞联合奥沙利铂二线治疗晚期结直肠癌的临床疗效及安全性。方法:收集郑州大学第一附属医院收治的经一线治疗失败的晚期结直肠癌患者57例,采用随机数字表法分为2组。28例采用TOMOX方案治疗,29例采用FOLFOX4方案治疗,评价2组疗效及不良反应。结果:TOMOX组和FOLFOX4组有效率分别为14.3%(4/28)和10.3%(3/29),疾病控制率分别为78.6%(22/28)和82.7%(24/29)(P0.05)。TOMOX组的无疾病进展生存期(PFS)为8.30个月,FOLFOX4组的PFS为8.10个月;TOMOX组的总生存期(OS)为15.40个月,FOLFOX4组的OS为14.10个月(P0.05)。TOMOX组中性粒细胞减少及心脏毒性的发生率低于FOLFOX4组,而TOMOX组转氨酶升高的发生率较FOLFOX4组高(P0.05),但多为Ⅰ~Ⅱ级,可耐受。结论:雷替曲塞联合奥沙利铂二线治疗晚期结直肠癌的疗效确切,且具有不良反应轻、易耐受等特点。
[Abstract]:Objective: To observe the clinical efficacy and safety of retrexed and oxaliplatin in the treatment of advanced colorectal cancer. Methods: 57 patients with advanced colorectal cancer who were treated in the First Affiliated Hospital of Zhengzhou University were collected and divided into 2 groups of.28 cases by random digital table method and 29 cases were treated with FOLFOX4 scheme. Results: the efficacy and adverse effects of 2 groups were evaluated. Results: the effective rates of group TOMOX and group FOLFOX4 were 14.3% (4/28) and 10.3% (3/29) respectively. The disease control rate was 78.6% (22/28) and 82.7% (24/29) (P0.05).TOMOX group was 8.30 months, and FOLFOX4 PFS was 8.10 months; the total survival period of the TOMOX group was 15.40 months. The incidence of neutrophils and cardiotoxicity in the 4 group of OS groups was lower than that in the group FOLFOX4, but the incidence of elevated transaminase in the TOMOX group was higher than that in the FOLFOX4 group (P0.05), but more than the class I (P0.05), but it was more tolerable. Conclusion: retrexed combined with oxaliplatin second line treatment for advanced colorectal cancer is effective and has adverse reaction. It should be light and easy to tolerate.
【作者单位】：郑州大学第一附属医院肿瘤科;
【基金】：河南省教育厅科学技术研究重点项目13A320638
【分类号】：R735.34

【相似文献】